CompletedNCT06058910

Bilistick Point-of-care System 2.0 Bilirubin Validation

Studying Bilirubin encephalopathy

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kettering Health Network
Principal Investigator: Jonathan D Toot, MD
Kettering Health
Intervention: Bilistick System 2.0 point-of-care testing device(diagnostic_test)
Enrollment: 80 enrolled
Eligibility: All sexes
Timeline: 2024 – 2024

Study locations (1)

Kettering Health Main Campus, Kettering, Ohio, United States

Collaborators

Bilimetrix s.r.l.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06058910 on ClinicalTrials.gov

Other trials for Bilirubin encephalopathy

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT04584983
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
The University of Texas Health Science Center, Houston

See all trials for Bilirubin encephalopathy →

← Back to all trials